Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger

Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.